Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Tracing the international arrivals of SARS-CoV-2 Omicron variants after Aotearoa New Zealand reopened its border

Jordan Douglas, David Winter, Xiaoyun Ren, Andrea McNeill, Michael Bunce, Nigel French, James Hadfield, Joep de Ligt, David Welch, Jemma L Geoghegan
doi: https://doi.org/10.1101/2022.07.12.22277518
Jordan Douglas
1Centre for Computational Evolution, School of Computer Science, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jordan.douglas{at}auckland.ac.nz
David Winter
2Institute of Environmental Science and Research, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoyun Ren
2Institute of Environmental Science and Research, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea McNeill
2Institute of Environmental Science and Research, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Bunce
2Institute of Environmental Science and Research, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nigel French
3Tāwharau Ora/School of Veterinary Science, Massey University, Palmerston North, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Hadfield
4Fred Hutchinson Cancer Research Centre, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joep de Ligt
2Institute of Environmental Science and Research, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Welch
1Centre for Computational Evolution, School of Computer Science, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jemma L Geoghegan
2Institute of Environmental Science and Research, Wellington, New Zealand
5Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Recently there has been a surge in emergent SARS-CoV-2 lineages that are able to evade both vaccine induced immunity as well as prior infection from the founding Omicron BA.1 and BA.2 lineages. These highly transmissible and evasive lineages are on the rise and include Omicron variants BA.2.12.1, BA.4, and BA.5. Aotearoa New Zealand recently reopened its borders to many travellers, without their need to enter quarantine. By generating 10,403 complete SARS-CoV-2 genomes classified as Omicron, we show that New Zealand is observing an influx of these immune-evasive variants through the border. Specifically, there has been a recent surge of BA.5 and BA.2.12.1 introductions into the community and these can be explained by the gradual return to pre-pandemic levels of international traveller arrival rates. We estimate there is one Omicron transmission event from the border to the community for every ∼5,000 passenger arrivals into the country, or around one introduction event per day at the current levels of travel. Given the waning levels of population immunity, this rate of importation presents the risk of a large wave in New Zealand during the second half of 2022. Genomic surveillance, coupled with modelling the rate at which new variants cross the border into the community, provides a lens on the rate at which new variants might gain a foothold and trigger new waves of infection.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Funding for genome sequencing of SARS-CoV-2 was provided by the Ministry of Health of New Zealand. We thank the diagnostic laboratories that performed the initial RT-PCRs and referred samples for sequencing as well as the public health units for providing epidemiological data. We thank all those who have contributed SARS-CoV-2 sequences to GISAID. JLG is funded by a New Zealand Royal Society Rutherford Discovery Fellowship (RDF-20-UOO-007) and New Zealand Health Research Council Grant (22/138). The authors wish to acknowledge the use of New Zealand eScience Infrastructure (NeSI) high performance computing facilities, consulting support and/or training services as part of this research. New Zealand's national facilities are provided by NeSI and funded jointly by NeSI's collaborator institutions and through the Ministry of Business, Innovation & Employment's Research Infrastructure programme. URL https://www.nesi.org.nz.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The New Zealand Ministry of Health gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced will be made available online

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 15, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Tracing the international arrivals of SARS-CoV-2 Omicron variants after Aotearoa New Zealand reopened its border
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Tracing the international arrivals of SARS-CoV-2 Omicron variants after Aotearoa New Zealand reopened its border
Jordan Douglas, David Winter, Xiaoyun Ren, Andrea McNeill, Michael Bunce, Nigel French, James Hadfield, Joep de Ligt, David Welch, Jemma L Geoghegan
medRxiv 2022.07.12.22277518; doi: https://doi.org/10.1101/2022.07.12.22277518
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Tracing the international arrivals of SARS-CoV-2 Omicron variants after Aotearoa New Zealand reopened its border
Jordan Douglas, David Winter, Xiaoyun Ren, Andrea McNeill, Michael Bunce, Nigel French, James Hadfield, Joep de Ligt, David Welch, Jemma L Geoghegan
medRxiv 2022.07.12.22277518; doi: https://doi.org/10.1101/2022.07.12.22277518

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3281)
  • Dentistry and Oral Medicine (362)
  • Dermatology (274)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1164)
  • Epidemiology (13340)
  • Forensic Medicine (19)
  • Gastroenterology (896)
  • Genetic and Genomic Medicine (5130)
  • Geriatric Medicine (479)
  • Health Economics (781)
  • Health Informatics (3253)
  • Health Policy (1138)
  • Health Systems and Quality Improvement (1189)
  • Hematology (427)
  • HIV/AIDS (1014)
  • Infectious Diseases (except HIV/AIDS) (14613)
  • Intensive Care and Critical Care Medicine (910)
  • Medical Education (475)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4900)
  • Nursing (261)
  • Nutrition (725)
  • Obstetrics and Gynecology (880)
  • Occupational and Environmental Health (795)
  • Oncology (2516)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (346)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (539)
  • Pediatrics (1297)
  • Pharmacology and Therapeutics (548)
  • Primary Care Research (554)
  • Psychiatry and Clinical Psychology (4193)
  • Public and Global Health (7482)
  • Radiology and Imaging (1702)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (478)
  • Sexual and Reproductive Health (495)
  • Sports Medicine (424)
  • Surgery (546)
  • Toxicology (71)
  • Transplantation (235)
  • Urology (203)